Physician profile
Constance Morfaw
NPI 1942562848
$2,286.43
in general payments reported to CMS, 2019-2025
22 companies · $581 in 2025
The $581 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.93 · 2022: $138 · 2023: $472 · 2024: $1,002 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,055.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $589.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $338.19 | 2021-2025 | |
| Pfizer INC. | $309.12 | 2022-2025 | |
| Exact Sciences Corporation | $153.84 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $144.90 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $135.84 | 2024-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $115.27 | 2022-2025 | |
| Glaxosmithkline, LLC. | $72.62 | 2022-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $56.66 | 2021-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $51.29 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $51.04 | 2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $41.34 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $37.20 | 2024 | |
| Boston Scientific Corporation | $34.07 | 2025 | Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.81 | 2021-2025 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $23.26 | 2024 | |
| Dexcom, INC. | $19.42 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $17.69 | 2025 | Flucelvax, Fluad |
| Amgen INC. | $17.61 | 2024 | Krystexxa |
| Corcept Therapeutics | $15.56 | 2021 | |
| Mylan Specialty L.P. | $15.40 | 2023 | Yupelri |
| Phadia US INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Morfaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.